Parkinson’s disease

Despite its large use, recommendations for the use of brain F-18 FDG-PET in clinical practice were still lacking. The European Academy of Neurology (EAN) and the European Association of Nuclear Medicine (EANM) promoted a concerted action with 7 specialists from the two Societies and a group of facilitators in order to make the point on this issue. Extensive literature review and analysis of available data led, together with expert opinion (Delphi consensus), to deliver these recommendations that cover practically all the main brain neurodegenerative conditions causing cognitive impairment.

Thank you for hosting applicants of the EAN Clinical Fellowship. How would you evaluate this EAN educational opportunity? This is a super opportunity for trainees in underserved areas and countries to gain practical and valuable experience of management of Parkinson’s disease and other movement disorder in a pragmatic and systematic manner.

The new CME article January 2018: “Long-term effects of cognitive rehabilitation on brain, functional outcome and cognition in Parkinson’s disease” is online now! Please log-in and browse to the LEARN section on the EAN Website and answer the questions! All… Continue Reading

      by Anna Sauerbier     The societal impact of pain (SIP) 2017 Steering Committee Meeting New techniques target protein clumps linked to Alzheimer’s and cancer Inside the solitary life of an Alzheimer’s sufferer E-health Tallinn 2017: i-prognosis… Continue Reading

Report from Dr Anca Adriana Arbune, from Bucharest, Romania visiting the Neurophysiology Department, Filadelfia Hospital, Dianalund, Denmark under the supervision of Prof. Sándor Beniczki.

For December 2017, we have selected: Dwivedi R, Ramanujam B, Chandra PS, et al. Surgery for drug-resistant epilepsy in children. NEJM 2017;377:1639-1647. Drug-resistant epilepsy can be particularly devastating in children due to the heavy impact on psychosocial aspects and quality of life of these little patients and their family.

In the middle of autumn, in the picturesque and colourful atmosphere of Moldavian nature, the neurological community of the country had the chance to organize and participate in one of the most important and valuable scientific event of the Society… Continue Reading

It is not new that human disease is imposing a burden on the sufferers and a challenge for the physician. While neurologists are having the privilege being physicians and have the single patient in our focus of attention, health economists take a different view. Their thinking is focusing on the burden of disease for the society and its economic implications. They look at the costs of disease in different terms. The classical measures for the burden of disease are the costs in terms of disability-adjusted life years (DALYs) which are defined as the sum of years of life lost due to the disease (YLLs) and years lived with the disease (YLDs) accounting for reduced life time with good quality of life due to the disability. Another important measure is the Socio-demographic Index (SDI) reflecting economic and educational development. There is big science behind all these calculations which I will not go into detail here.

For November 2017, we have selected: Mittal S, Bjørnevik K, Im DS, et al. ß2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson’s disease. Science 2017;140:2295-2305. Disturbed proteostasis of α-synuclein is now thought to play a critical role in the pathogenesis of Parkinson’s disease (PD). Physiological functions of this protein include synaptic transport as well as involvement in the metabolism of membrane phospholipids, and in the differentiation and survival of dopaminergic neurons.

Report from Dr Meri Grigoryan, from Yerevan, Armenia visiting the Department of Neurology, Universitatsklinikum Heidelberg, Germany under the supervision of prof. Peter Ringleb

For October 2017, we have selected: Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J. The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study. Brain 2017;140:2295-2305. Patients with myotonia congenita and paramyotonia congenita can be disabled by the myotonic phenomenon in the activities of daily living, with a huge impact on their quality of life.

We are delighted to inform that our media partner touchNEUROLOGY has produced the following Interviews during the EAN congress 2017 in Amsterdam: EAN 2017 Peter Goadsby Interview about premonitory-like symptomatology in migraine, EAN 2017 Patrick Vermersch Interview on teriflunomide’s role… Continue Reading